ISIchiro Shimizu

Ichiro Shimizu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ichiro Shimizu has a total of 27 co-authors. Here are the top co-authors by number of shared publications:

  • Susumu Ito

    Department of Digestive and Cardiovascular Medicine, Tokushima University Graduate School of Medicine, Tokushima, Japan

    4 shared publications
  • Takahiro Horie

    Department of Internal Medicine, Miyoshi Prefectural Hospital and

    2 shared publications
  • Arata Iuchi

    Department of Internal Medicine, Miyoshi Prefectural Hospital and

    1 shared publication
  • Fei Liu

    Department of Biochemistry, Shanghai Medical University, Shanghai, China

    1 shared publication
  • Guangming Lu

    Second Department of Internal Medicine, Tokushima University School of Medicine, Tokushima, and

    1 shared publication
  • Hirohito Honda

    Second Department of Internal Medicine, Tokushima University School of Medicine, Tokushima, and

    1 shared publication

Latest Publications

  • Protection of estrogens against the progression of chronic liver disease

    by Ichiro Shimizu, Susumu Ito

    Hepatitis C virus infections are recognized as a major causative factor of chronic liver disease. A characteristic feature of chronic hepatitis C, alcoholic liver disease and non‐alcoholic fatty liver disease is hepatic steatosis. Hepatic steatosis leads to an increase in lipid peroxidation in hepatocytes, which, in turn, activates hepatic stellate cells (HSCs). HSCs are also thought to be the primary target cells for inflammatory and oxidative stimuli, and to produce extracellular matrix components. Based on available clinical information, chronic hepatitis C appears to progress more rapidly in men than in women, and cirrhosis is predominately a disease of men and postmenopausal women. Estradiol is a potent endogenous antioxidant. Hepatic steatosis was reported to become evident in an aromatase‐deficient mouse and was diminished in animals after treatment with estradiol. Our previous studies showed that estradiol suppressed hepatic fibrosis in animal models, and attenuated HSC activation by suppressing the generation of reactive oxygen species in primary cultures. Variant estrogen receptors were found to be expressed to a greater extent in male patients with chronic liver disease than in female subjects. A better understanding of the basic mechanisms underlying the gender‐associated differences observed in the progression of chronic liver disease would provide valuable information relative to the search for effective antifibrogenic therapies.


  • Effects of idoxifene and estradiol on NF‐κB activation in cultured rat hepatocytes undergoing oxidative stress

    by Toshihiro Omoya, Ichiro Shimizu, Yajun Zhou, Yoshihito Okamura, Hiroshi Inoue, Guangming Lu, Mina Itonaga, Hirohito Honda, Masahiro Nomura, Susumu Ito

    Background/Aims: Idoxifene is a tissue‐specific selective estrogen receptor modulator. Estradiol is a potent endogenous antioxidant, and nuclear factor κB (NF‐κB) is a key transcription factor that induces multiple genes in response to inflammation or oxidative stress. The aim of this study was to explore the inhibitory effects of idoxifene and estradiol on NF‐κB activation in hepatocytes in a state of oxidative stress. Methods: Lipid peroxidation was induced in cultured rat hepatocytes by incubation with ferric nitrilotriacetate solution. NF‐κB activity was evaluated by electrophoretic mobility shift assay. Results: The oxidative stress‐induced activation of NF‐κB and degradation of IκB‐α were maximal at 3–5 h, with an increase in lactate dehydrogenase (LDH) and malondialdehyde (MDA) secretion into the culture medium. Treatment with idoxifene and estradiol inhibited IκB‐α degradation and NF‐κB activation through the attenuation of hepatocyte oxidative bursts and decreased extracellular levels of LDH and MDA. In addition, idoxifene and estradiol inhibited lipid peroxidation in rat liver mitochondria. A potent NF‐κB inhibitor, pyrrolidine dithiocarbamate, prevented NF‐κB activation by inhibition of IκB‐α degradation and decreased LDH and MDA levels, suggesting that NF‐κB might be a regulator in a genetic response to increase oxidative stress‐induced hepatic injury. Conclusions: These findings suggest that idoxifene and estradiol function as antioxidants and protect hepatocytes from inflammatory cell injury.


  • Colonoscopic extiripation of whipworms in patient with acute abdomen‐like symptoms

    by Takahiro Horie, Ichiro Shimizu, Tatsuro Ogata, Takasi Oshima, Miyuki Mihara, Masatoshi Yamashita, Yuji Ozaki, Koji Yamamoto, Arata Iuchi, Susumu Ito


  • Open Access

    Effects of Sho–Saiko–To, A Japanese Herbal Medicine, on Hepatic Fibrosis in Rats

    by Ichiro Shimizu, Yue-Rong Ma, Yoko Mizobuchi, Fei Liu, Tetsuo Miura, Yoichiro Nakai, Mitugi Yasuda, Masako Shiba, Takahiro Horie, Sakae Amagaya, et al.

    It has been shown that lipid peroxidation is associated with hepatic fibrosis and stellate cell activation. Sho–saiko–to (TJ–9) is an herbal medicine, which is commonly used to treat chronic hepatitis in Japan, although the mechanism by which TJ–9 protects against hepatic fibrosis is not known. As a result, we assayed the preventive and therapeutic effects of TJ–9 on experimental hepatic fibrosis, induced in rats by dimethylnitrosamine (DMN) or pig serum (PS), and on rat stellate cells and hepatocytes in primary culture, and assessed the antioxidative activities and the active components of TJ–9. Male Wistar rats were given a single intraperitoneal injection of 40 mg/kg DMN or 0.5 mL PS twice weekly for 10 weeks. In each model, rats were fed a basal diet throughout, or the same diet, which also contained 1.5% TJ–9, for 2 weeks before treatment or for the last 2 weeks of treatment. TJ–9 suppressed the induction of hepatic fibrosis, increased hepatic retinoids, and reduced the hepatic levels of collagen and malondialdehyde (MDA), a production of lipid peroxidation. Immunohistochemical examination showed that TJ–9 reduced the deposition of type I collagen and the number of α–smooth muscle actin (α–SMA) positive–stellate cells in the liver and inhibited, not only lipid peroxidation in cultured rat hepatocytes that were undergoing oxidative stress, but also the production of type I collagen, α–SMA expression, cell proliferation, and oxidative burst in cultured rat stellate cells. In addition, TJ–9 inhibited Fe2+/adenosine 5′–diphosphate–induced lipid peroxidation in rat liver mitochondria in a dose–dependent manner and showed radical scavenging activity. Among the active components of TJ–9, baicalin and baicalein were found to be mainly responsible for the antioxidative activity. These findings suggest that Sho–saiko–to (TJ–9) functions as a potent antifibrosuppressant by inhibition of lipid peroxidation in hepatocytes and stellate cells in vivo.